Phytohealth Corporation (4108) AI Stock Analysis

Phytohealth Corporation

(TWSE:4108)

Select Model

Rating:47Neutral

Price Target:TWD 10.50▲(1.45% Upside)

Action:initiatedcoverage

Date:11/10/26

Score primarily reflects mixed financials with balance sheet strength outweighed by weak profitability and cash burn, compounded by bearish technicals and poor valuation from sustained losses.

Positive Factors

Very low leverageExtremely low leverage and declining total debt provide a durable financial cushion. This reduces balance-sheet pressure and preserves flexibility to fund operations or strategic initiatives without relying heavily on additional borrowing over the next several quarters.

Negative Factors

Severe operating and net lossesDeep operating and net losses show that the current business is not yet economically scaled. The gap between gross profit and operating costs remains substantial, creating a durable earnings risk until expenses are reduced or revenue expands materially.

Phytohealth Corporation (4108) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 2.07B
Dividend Yield: ―
Average Volume (3M): 289.13K
Price to Earnings (P/E): -48.2
Beta (1Y): 0.48
Revenue Growth: 3.62%
EPS Growth: 34.40%
Country: TW
Employees: 84
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Phytohealth Corporation Business Overview & Revenue Model

Company Description

Established in 1998 and headquartered in Taipei, Taiwan, PhytoHealth Corporation specializes in the research, development, production, and commercialization of a diverse portfolio including pharmaceutical products, cosmetic lines, specific over-the-c...

Phytohealth Corporation Financial Statement Overview

Summary

Strong balance sheet with minimal debt and solid equity provides stability, but declining revenue, sharply lower margins, persistent net losses, and negative cash flows indicate significant operational challenges.

Income Statement

22Negative

Balance Sheet

88Very Positive

Cash Flow

48Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	143.43M	134.58M	153.56M	162.49M	135.47M	168.94M
Gross Profit	47.47M	41.29M	64.01M	67.64M	57.03M	78.31M
EBITDA	-134.26M	-60.66M	-54.86M	-20.70M	-61.97M	-42.30M
Net Income	-43.37M	-58.20M	-73.50M	-47.12M	-115.03M	-78.02M
Balance Sheet
Total Assets	2.41B	2.35B	2.44B	2.35B	2.36B	2.47B
Cash, Cash Equivalents and Short-Term Investments	1.00B	1.07B	1.08B	1.27B	1.36B	1.41B
Total Debt	21.27M	15.73M	18.34M	28.11M	30.19M	30.93M
Total Liabilities	58.22M	59.42M	71.29M	79.85M	87.17M	81.56M
Stockholders Equity	1.94B	1.87B	1.90B	1.93B	1.91B	1.98B
Cash Flow
Free Cash Flow	-19.55M	-45.26M	-55.18M	-59.50M	-61.55M	-81.45M
Operating Cash Flow	-15.14M	-39.72M	-50.13M	-54.77M	-59.95M	-68.24M
Investing Cash Flow	3.50M	114.82M	-135.14M	26.25M	76.92M	-581.14M
Financing Cash Flow	-10.84M	-11.04M	145.24M	-9.18M	-10.52M	682.23M

Phytohealth Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4108 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:8432	85Outperform	TWD 2.36B	11.34	―	4.24%	20.56%	67.85%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4747	53Neutral	TWD 1.60B	-25.78	―	2.99%	4.56%	-172.55%
TW:4108	47Neutral	TWD 2.06B	-48.21	―	―	3.62%	34.40%
TW:4168	41Neutral	TWD 2.38B	-8.40	―	―	-36.49%	-29.76%

* General Sector Average

Performance Comparison

TW:4108 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4108	Phytohealth Corporation	10.35	-3.90	-27.37%
TW:4168	GlycoNex, Inc.	21.15	-1.05	-4.73%
TW:4747	Johnson Chemical Pharmaceutical Works Co., Ltd.	17.55	-14.17	-44.68%
TW:7860	Teh Seng Pharmaceutical Mfg Co Ltd	71.20	-1.47	-2.02%
TW:7888	Libo Pharma Corp.	24.60	-20.55	-45.51%
TW:8432	TSH Biopharm Corp. Ltd.	61.50	9.01	17.17%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Phytohealth Corporation AI Stock Analysis